We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Pfizer Acquires COVID-Flu Test Developer Lucira Health for USD 36.4 Million

By LabMedica International staff writers
Posted on 02 May 2023
Print article
Image: The Lucira COVID-19 Test provides 98% accurate, lab-quality results in 30 minutes or less (Photo courtesy of Lucira)
Image: The Lucira COVID-19 Test provides 98% accurate, lab-quality results in 30 minutes or less (Photo courtesy of Lucira)

Pfizer Inc. (New York, NY, USA) has acquired Lucira Health, Inc. (Emeryville, CA, USA) for USD 36.4 million in a bankruptcy auction.

Lucira filed for bankruptcy in February 2023, just two days before receiving FDA Emergency Use Authorization (EUA) for the first over-the-counter (OTC) at-home diagnostic test capable of differentiating and detecting influenza A and B. The COVID-19 & Flu Home Test is a single-use at-home test kit that delivers results from self-collected nasal swab samples in about 30 minutes. Lucira had previously received the first FDA EUA for an at-home rapid self-test, the Lucira COVID-19 All-in-One Test Kit, in November 2020, and the company announced in April 2021 that it had secured OTC EUA for its Lucira Check It test kit for SARS-CoV-2. The company's tests use a handheld battery-powered real-time testing instrument with nasal swab samples and loop-mediated isothermal amplification to provide results in 30 minutes. In November 2022, the FDA granted the company EUA for point-of-care use of its RT-LAMP-based COVID-19 and flu test.

During the COVID-19 pandemic, Lucira experienced rapid growth as demand for the company's COVID-19 test kits increased. When announcing its Chapter 11 plans, Lucira stated that a lengthy EUA process for its COVID-19 and influenza test had proved expensive, leading to the bankruptcy filing and sale process. Lucira also mentioned in a previous SEC filing that a lack of clinical data had forced the company to restrict its combination test to point-of-care use until it could obtain more prospective clinical data.

Related Links:
Pfizer Inc. 
Lucira Health, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.